- Health Canada has accepted the NDS for FILSUVEZ (birch triterpenes) topical gel and granted Priority Review for treating wounds associated with dystrophic and junctional epidermolysis bullosa (EB), reducing the review timeline to ~180 days.
- If approved, FILSUVEZ could become the first therapy specifically approved in Canada for EB-related wounds, addressing a major unmet need in this rare genetic skin disorder.
- The submission is backed by data from the Phase III EASE trial, which evaluated the safety and efficacy of FILSUVEZ in patients with dystrophic and junctional EB.
- Already approved in the U.S., EU, and Australia, FILSUVEZ brings hope for Canadian patients living with chronic wounds, pain, and significant daily care challenges associated with EB.
Takeaways:
If approved, FILSUVEZ would become Canada’s first treatment specifically for EB-related wounds, addressing a severe unmet need for patients with chronic, painful skin breakdown and heavy daily care burdens. The NDS is supported by Phase III EASE trial data on safety and efficacy, and with approvals already in the U.S., EU, and Australia, FILSUVEZ could rapidly fill a critical gap in Canadian EB care and reposition the market for this ultra-rare disease.
Source: Globenewswire
